Browsing by Subject "Precocious puberty"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Central precocious puberty in spina bifida children: Guidelines for the care of people with spina bifida
    (IOS Press, 2020) Almutlaq, Nourah; O’Neil, Joseph; Fuqua, John S.; Pediatrics, School of Medicine
    Children with spina bifida are at greater risk of developing central precocious puberty (CPP) compared to others. Therefore, early recognition and timely referral for further evaluation by a pediatric endocrinologist allows appropriate management that reduces the impact of CPP. This article discusses the diagnosis and management of CPP in children with spina bifida. This guideline was developed for SB Transition Healthcare Guidelines from the 2018 Spina Bifida Association's Fourth Edition of the Guidelines for the Care of People with Spina Bifida.
  • Thumbnail Image
    Item
    Incidence and Characteristics of Pseudoprecocious Puberty Because of Severe Primary Hypothyroidism
    (Elsevier, 2013) Cabrera, Susanne M.; DiMeglio, Linda A.; Eugster, Erica A.; Pediatrics, School of Medicine
    Severe primary hypothyroidism is a presumed rare cause of pseudoprecocious puberty (PsPP). Here, we report a 24% incidence of PsPP among 33 children with profound hypothyroidism. Those with PsPP were older and trended toward a higher thyroid stimulating hormone. Increased awareness of PsPP can hasten diagnosis and appropriate treatment.
  • Thumbnail Image
    Item
    Treatment of Central Precocious Puberty
    (Oxford University Press, 2019-03-28) Eugster, Erica A.; Pediatrics, School of Medicine
    Long-acting analogs of GnRH (GnRHas) have been the gold-standard treatment of central precocious puberty (CPP) worldwide and have an enviable track record of safety and efficacy. Recent years have witnessed much growth in the availability of longer-acting and sustained-release forms of GnRHas. Although all available agents appear promising, limited long-term follow-up and/or comparative data are available. In this review, important issues pertaining to the treatment of children with CPP are discussed. In addition to an assessment of the newer extended-release GnRHa formulations, a delineation of factors essential in determining which children should be treated is offered. Outstanding uncertainties in clinical management are highlighted and areas in need of future research identified. Literature searches for this review were performed in PubMed and OVID, with a focus on English-language publications using the terms "central precocious puberty" and "treatment."